Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own0.80% Shs Outstand87.39M Perf Week11.93%
Market Cap8.05B Forward P/E- EPS next Y-2.17 Insider Trans-20.45% Shs Float79.64M Perf Month-8.67%
Income-173.40M PEG- EPS next Q-0.43 Inst Own95.50% Short Float14.52% Perf Quarter-24.38%
Sales31.40M P/S256.38 EPS this Y-46.20% Inst Trans0.61% Short Ratio11.40 Perf Half Y73.81%
Book/sh4.40 P/B19.26 EPS next Y-16.00% ROA-31.20% Target Price113.65 Perf Year188.79%
Cash/sh5.08 P/C16.67 EPS next 5Y-11.30% ROE-46.20% 52W Range25.60 - 121.16 Perf YTD-6.82%
Dividend- P/FCF- EPS past 5Y-12.30% ROI-33.30% 52W High-29.84% Beta1.64
Dividend %- Quick Ratio5.80 Sales past 5Y66.80% Gross Margin- 52W Low232.07% ATR6.87
Employees279 Current Ratio5.80 Sales Q/Q467.90% Oper. Margin- RSI (14)51.81 Volatility7.45% 8.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.50% Profit Margin- Rel Volume0.61 Prev Close84.73
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 AMC Payout- Avg Volume1.01M Price85.01
Recom1.90 SMA204.56% SMA50-5.88% SMA20032.44% Volume389,665 Change0.33%
Feb-26-21Initiated BofA Securities Buy $115
Feb-26-21Downgrade Wedbush Outperform → Neutral
Feb-11-21Downgrade Citigroup Buy → Neutral
Jan-27-21Resumed H.C. Wainwright Neutral $108
May-13-20Initiated H.C. Wainwright Buy $42
Mar-04-20Initiated Barclays Overweight $40
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
Aug-09-19Initiated BTIG Research Buy $27
Jul-22-19Initiated Cantor Fitzgerald Overweight
Jul-12-19Initiated Oppenheimer Outperform $27
Jun-13-19Initiated Mizuho Buy
Jun-07-19Initiated ROTH Capital Neutral $20
May-31-19Initiated Guggenheim Buy
May-24-19Resumed Citigroup Buy $26
Mar-28-19Initiated SVB Leerink Outperform $20
Apr-15-21 12:29PM  
Apr-06-21 02:00PM  
Apr-02-21 06:20AM  
Mar-26-21 11:31AM  
Mar-25-21 07:00AM  
05:55AM  
Mar-08-21 07:00AM  
Feb-27-21 09:23AM  
01:43AM  
Feb-25-21 12:48PM  
03:30AM  
Feb-24-21 04:55PM  
04:01PM  
03:15PM  
Feb-22-21 04:01PM  
Feb-08-21 12:49AM  
Jan-29-21 06:56AM  
Jan-28-21 06:42AM  
Jan-11-21 08:02AM  
Jan-08-21 04:26PM  
09:01AM  
08:50AM  
Jan-07-21 04:24PM  
Jan-06-21 12:30AM  
Jan-05-21 06:23AM  
Jan-04-21 04:01PM  
Dec-30-20 10:42AM  
07:18AM  
Dec-29-20 09:37AM  
Dec-28-20 10:43AM  
Dec-23-20 09:21AM  
Dec-22-20 04:30PM  
Dec-09-20 08:42AM  
Dec-08-20 01:22PM  
Dec-07-20 04:20PM  
03:33PM  
12:39PM  
10:00AM  
Dec-06-20 10:05AM  
Dec-05-20 11:32AM  
Dec-04-20 04:01PM  
10:43AM  
Nov-30-20 08:00AM  
Nov-12-20 04:01PM  
Nov-10-20 05:54AM  
Nov-07-20 02:00AM  
Nov-05-20 06:05PM  
04:01PM  
03:45PM  
08:00AM  
Nov-03-20 09:15AM  
Nov-02-20 07:00AM  
Oct-15-20 08:00AM  
Sep-30-20 08:00AM  
Sep-11-20 10:11AM  
Sep-04-20 08:00AM  
Aug-19-20 08:00AM  
Aug-11-20 08:19AM  
08:00AM  
Aug-05-20 05:55PM  
04:01PM  
Aug-04-20 04:01PM  
Jul-29-20 04:01PM  
Jul-28-20 12:32PM  
Jul-26-20 07:40AM  
Jul-21-20 08:11AM  
Jul-16-20 11:06AM  
Jul-14-20 08:00AM  
Jul-10-20 10:18AM  
Jul-09-20 08:00AM  
Jun-15-20 10:50PM  
01:44PM  
Jun-13-20 07:50AM  
Jun-11-20 04:01PM  
Jun-09-20 05:29PM  
02:10PM  
12:49AM  
Jun-08-20 04:01PM  
May-20-20 08:00AM  
May-15-20 06:18AM  
May-12-20 04:30PM  
01:40PM  
May-11-20 05:15PM  
04:01PM  
May-08-20 08:46AM  
May-05-20 09:18PM  
04:01PM  
May-04-20 04:01PM  
09:38AM  
Apr-30-20 08:33AM  
Apr-29-20 07:11AM  
Apr-28-20 04:30PM  
12:33PM  
Apr-14-20 09:13AM  
Apr-10-20 12:00PM  
Apr-08-20 11:30AM  
10:05AM  
10:04AM  
Apr-06-20 09:08AM  
Apr-04-20 09:07AM  
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAHL CINDYSee RemarksApr 01Option Exercise3.2130,00096,199138,048Apr 02 06:03 PM
TAHL CINDYSee RemarksApr 01Sale83.8130,0002,514,329108,048Apr 02 06:03 PM
Valamehr BahramChief Development OfficerMar 15Sale92.3525,0002,308,77295,740Mar 16 04:05 PM
Shoemaker Daniel DChief Scientific OfficerMar 08Sale81.7425,0002,043,42873,020Mar 09 04:02 PM
Wolchko J ScottPresident and CEOFeb 18Option Exercise6.6220,000132,400413,793Feb 19 04:07 PM
Wolchko J ScottPresident and CEOFeb 18Sale102.0120,0002,040,258393,793Feb 19 04:07 PM
Wolchko J ScottPresident and CEOJan 22Option Exercise5.3230,000159,700423,793Jan 22 06:23 PM
Wolchko J ScottPresident and CEOJan 22Sale98.2930,0002,948,611393,793Jan 22 06:23 PM
Wolchko J ScottPresident and CEOJan 21Option Exercise2.7330,00081,900423,793Jan 22 06:23 PM
Wolchko J ScottPresident and CEOJan 21Sale103.0530,0003,091,357393,793Jan 22 06:23 PM
TAHL CINDYGeneral Counsel and SecretaryJan 19Option Exercise2.9035,000101,500125,035Jan 21 07:08 PM
TAHL CINDYGeneral Counsel and SecretaryJan 19Sale114.7635,0004,016,63990,035Jan 21 07:08 PM
Shoemaker Daniel DChief Scientific OfficerJan 11Sale110.813,253360,47783,609Jan 12 08:38 PM
TAHL CINDYGeneral Counsel and SecretaryJan 11Sale110.813,254360,58790,035Jan 12 08:39 PM
Valamehr BahramChief Development OfficerJan 11Sale110.813,254360,58877,727Jan 12 08:40 PM
Wolchko J ScottPresident and CEOJan 11Sale110.818,587951,556350,562Jan 12 08:41 PM
Redmile Group, LLCDirectorJan 08Buy85.50327,48527,999,96812,957,222Jan 12 04:16 PM
Wolchko J ScottPresident and CEOJan 08Sale117.1060,8207,122,217359,149Jan 12 08:41 PM
Valamehr BahramChief Development OfficerJan 08Sale117.106,230729,55280,981Jan 12 08:40 PM
TAHL CINDYGeneral Counsel and SecretaryJan 08Sale117.106,229729,43493,289Jan 12 08:39 PM
Shoemaker Daniel DChief Scientific OfficerJan 08Sale117.106,229729,43486,862Jan 12 08:38 PM
Wolchko J ScottPresident and CEODec 17Option Exercise6.6220,000132,400439,969Dec 18 04:01 PM
Wolchko J ScottPresident and CEODec 17Sale91.8220,0001,836,352419,969Dec 18 04:01 PM
Valamehr BahramChief Development OfficerDec 14Option Exercise2.9025,00072,500112,211Dec 15 04:01 PM
Valamehr BahramChief Development OfficerDec 14Sale97.7825,0002,444,47787,211Dec 15 04:01 PM
Shoemaker Daniel DChief Scientific OfficerNov 16Sale51.8325,0001,295,74693,091Nov 16 05:12 PM
Wolchko J ScottPresident and CEONov 13Option Exercise5.7330,000172,008430,123Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 13Sale51.0330,0001,530,900419,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Option Exercise2.7330,00081,900449,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Sale52.7230,0001,581,524419,969Nov 16 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Option Exercise2.8219,28254,340118,800Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Sale50.6319,282976,25299,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Option Exercise2.7351,519140,647151,037Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Sale50.4151,5192,597,14099,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Option Exercise2.7329,19979,713128,717Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Sale50.2529,1991,467,21299,518Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Option Exercise2.7335,00095,550134,518Oct 02 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Sale40.7435,0001,426,06599,518Oct 02 04:01 PM
Valamehr BahramChief Development OfficerSep 14Option Exercise2.7525,00068,778112,211Sep 16 04:02 PM
Valamehr BahramChief Development OfficerSep 14Sale36.2825,000907,02487,211Sep 16 04:02 PM
Shoemaker Daniel DChief Scientific OfficerSep 14Sale36.3025,000907,540118,091Sep 16 04:01 PM
Redmile Group, LLCDirectorJun 11Buy28.311,412,92839,999,99212,629,737Jun 17 08:25 PM